Get the Stockscreener App
2.75
1.10%
0.03
Neuraxis Inc stock is traded at $2.75, with a volume of 51,921.
It is up +1.10% in the last 24 hours and down -13.52% over the past month.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
See More
Previous Close:
$2.72
Open:
$2.72
24h Volume:
51,921
Relative Volume:
0.14
Market Cap:
$27.15M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-3.4094
EPS:
-0.8066
Net Cash Flow:
-
1W Performance:
-11.58%
1M Performance:
-13.52%
6M Performance:
+18.53%
1Y Performance:
+6.17%
1-Day Range:
$2.67
$2.75
1-Week Range:
$2.67
$3.15
52-Week Range:
$1.33
$6.20
Neuraxis Inc Stock (NRXS) Company Profile
Name
Neuraxis Inc
Sector
Industry
Phone
(812) 689-0791
Address
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
2.75 | 27.16M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.83 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
640.41 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.76 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.44 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.43 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Neuraxis Inc Stock (NRXS) Latest News
How supply shortages influence Neuraxis Inc. stock2025 Historical Comparison & Risk Controlled Daily Plans - newser.com
Will NeurAxis Inc. continue its uptrendTrade Signal Summary & Safe Entry Zone Identification - newser.com
Using Ichimoku Cloud for NeurAxis Inc. technicalsInsider Selling & Verified Entry Point Signals - newser.com
Can NeurAxis Inc. stock hit analyst price targetsWeekly Gains Report & Reliable Intraday Trade Plans - newser.com
Is Neuraxis Inc. stock a defensive play amid uncertaintyMarket Activity Recap & Proven Capital Preservation Tips - newser.com
Ranking NeurAxis Inc. among high performing stocks via toolsBond Market & Comprehensive Market Scan Insights - newser.com
Is Neuraxis Inc. stock undervalued historicallyWeekly Gains Report & Weekly Watchlist for Hot Stocks - newser.com
Will NeurAxis Inc. stock recover faster than marketPortfolio Risk Summary & Verified Entry Point Signals - newser.com
Risk vs reward if holding onto NeurAxis Inc.Weekly Risk Report & Consistent Income Trade Ideas - newser.com
Predicting NeurAxis Inc. trend using moving averagesJuly 2025 Patterns & Risk Controlled Daily Plans - newser.com
Why Neuraxis Inc. stock is favored by hedge fundsJuly 2025 Catalysts & Growth Focused Entry Point Reports - newser.com
Can Neuraxis Inc. stock hold up in economic slowdownPortfolio Gains Summary & Target Return Focused Stock Picks - newser.com
Will Neuraxis Inc. stock profit from automation waveSwing Trade & Reliable Volume Spike Trade Alerts - newser.com
Analyzing NeurAxis Inc. with multi timeframe chartsTrade Signal Summary & Real-Time Volume Triggers - newser.com
How resilient is NeurAxis Inc. stock in market downturnsWeekly Profit Analysis & Consistent Return Investment Signals - newser.com
Why NeurAxis Inc. stock remains on buy listsCEO Change & Fast Exit Strategy with Risk Control - Fundação Cultural do Pará
Neuraxis Inc Stock (NRXS) Financials Data
There is no financial data for Neuraxis Inc (NRXS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.15%
1.71%
Cap:
|
Volume (24h):